Agile Therapeutics, Inc. Stock

Equities

AGRX

US00847L3087

Biotechnology & Medical Research

Delayed OTC Markets 03:56:36 2024-04-18 pm EDT 5-day change 1st Jan Change
0.37 USD +0.61% Intraday chart for Agile Therapeutics, Inc. -11.95% -81.03%
Sales 2022 10.88 Sales 2023 19.59 Capitalization 4.9M
Net income 2022 -25M Net income 2023 -14M EV / Sales 2022 568,219 x
Net cash position 2022 3.04M Net cash position 2023 385K EV / Sales 2023 230,324 x
P/E ratio 2022
-0.19 x
P/E ratio 2023
-0.29 x
Employees 19
Yield 2022 *
-
Yield 2023
-
Free-Float 99.56%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.61%
1 week-11.95%
Current month+8.82%
1 month-33.93%
3 months-76.58%
6 months-79.33%
Current year-81.03%
More quotes
1 week
0.36
Extreme 0.356
0.41
1 month
0.20
Extreme 0.2
0.61
Current year
0.20
Extreme 0.2
1.98
1 year
0.20
Extreme 0.2
7.00
3 years
0.20
Extreme 0.2
3 940.00
5 years
0.20
Extreme 0.2
9 530.40
10 years
0.20
Extreme 0.2
26 380.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 04-01-31
Director of Finance/CFO 57 10-11-30
Chief Tech/Sci/R&D Officer 58 20-08-16
Members of the board TitleAgeSince
Chief Executive Officer 65 04-01-31
Director/Board Member 68 16-07-27
Director/Board Member 67 14-11-17
More insiders
Date Price Change Volume
24-04-18 0.37 +0.61% 15,137
24-04-17 0.3678 -4.62% 119,671
24-04-16 0.3856 +4.10% 123,040
24-04-15 0.3704 +1.74% 35,158
24-04-12 0.364 -13.35% 78,790

Delayed Quote OTC Markets, April 18, 2024 at 03:56 pm EDT

More quotes
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
More about the company